DSL 201
Alternative Names: DSL-201Latest Information Update: 03 Apr 2026
At a glance
- Originator DSciLab
- Class Antispasmodics
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spasm
Most Recent Events
- 18 Mar 2026 Preclinical trials in Spasm in China (Parenteral) (DSciLab pipeline, March 2026)
- 31 Dec 2025 DSciLab plans to submit IND application for DSL 201 in 2025 (DSciLab pipeline, March 2026)